House Committee Seeks Answers From FDA About Anticoagulant Adverse Events
WASHINGTON, D.C. — Two members of the House Energy and Commerce Committee on Sept. 2 asked the Food and Drug Administration what steps, if any, the agency is taking to address...To view the full article, register now.
Already a subscriber? Click here to view full article